CER Daily Newsfeed

RWE Is Not Optional, It's Essential

(8/25, Clinical Leader) comments “...In this Q&A, [Jennifer Timoshanko, head of medical strategy, bone health, UCB] explains why RWE is a valuable alternative to RCTs and shares best practices for collecting it, including using systematic literature reviews to map existing knowledge, applying rigorous and transparent methodologies for data selection, and combining multiple data sources to address evidence gaps.” Full

Pharma Data More Important Than Ever

(8/23, Pharma Marketing Network) reports “...Companies like Pfizer and AstraZeneca are investing heavily in RWE platforms to demonstrate outcomes that resonate with both regulators and payers. For example, data from electronic health records, insurance claims, and wearable devices now inform decision-making. This not only helps justify reimbursement decisions but also improves clinical practice.” Full

Gaps in Observational Data Challenge Understanding of Infection Risk in MS Treatments

(8/23, Skylar Jeremias, AJMC) reports “Real-world evidence on infection risks from multiple sclerosis treatments remains limited, with inconsistent findings compared with clinical trials and significant gaps in data for newer therapies and specific infection types.” Full